Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

them for signs of anti-tumor activity. We look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial is to assess overall tumor response rate. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. All tumor responses in the trial are being evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients may continue to receive bavituximab as solo therapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

According to the RECIST criteria, patients are categorized as having "stable disease" ("SD") if they have less than a 20% increase to a 30% reduction in the sum of the target lesions, and they are categorized as having a "partial response" ("PR") if they experience greater than a 30% reduction in the sum of target lesions. In addition, to be assigned a status of SD or PR, patients cannot have the appearance of any new lesions.

According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to h
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015 Today AmerisourceBergen, a global ... distribution centers in Olive Branch, MS ... Newburgh, NY . The facilities will operate ... improve product access, increase supply chain efficiency and enhance ... of the company,s ongoing investments, more than $1 billion ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jrlgdj/electrophysiology ) has ... by Product {Diagnostic Catheter (Conventional, Advanced, Ultrasound)), Ablation ... Generator, ICE, X-ray)) & Indication (AF, VT, WPW) ... their offering. The global electrophysiology (EP) ... CAGR of 10.3% from 2014 to 2019 ...
(Date:6/2/2015)... MELBOURNE, Australia , June 2, 2015 /PRNewswire/ ... has successfully raised AUD$14.8 million to rapidly ... its lead Personal KinetiGraph™ (PKG™) mobile health ... Partners has contributed further capital in the ... funds, industry veterans, high net worth individuals ...
Breaking Medicine Technology:AmerisourceBergen to Build Three New Distribution Centers 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 3Global Kinetics Corporation Closes AUD$14.8 Million Capital Raising 2Global Kinetics Corporation Closes AUD$14.8 Million Capital Raising 3
... 2011 Tocagen Inc. today announced the ... such as those with glioblastoma multiforme (GBM, Grade 4), ... The multicenter, open-label study is evaluating the safety ... administered intratumorally followed by cycles of the prodrug 5-fluorocytosine ...
... KNDL ), a leading, global full-service ... of Pierre Geoffroy, MD, CM, MSc, FCFP as ... brings nearly two decades of clinical development experience ... the development of Early Stage programs for customers ...
Cached Medicine Technology:Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma 2Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage 2Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage 3
(Date:6/2/2015)... Acara Partners has seen a spike in demand for ... as is now required by recent Google search algorithm changes. ... several new clients in the medical aesthetics vertical, are anxious ... meet Google’s new requirements,” commented Fran Acunzo, CEO of Acara ... education, non-profits, and the business world.” , Back in ...
(Date:6/2/2015)... Vancouver, BC (PRWEB) June 02, 2015 ... to announce the opening of Surrey’s first ... cities and boasts a diverse, young community, ... communities. http://www.theglobeandmail.com/news/british-columbia/four-reasons-bcs-fastest-growing-city-is-a-political-powerhouse/article21408253/ , Until now ... have had to come into Vancouver ...
(Date:6/2/2015)... 2015 ANT Wireless, proven innovator ... Pole Engineering’s (NPE) announcement of three next generation ... WASP-PoE-2 and WASP-PoE-3. WASP is a standalone ANT ... bridge solution that allows data collected from low-power ... Ethernet networks. , The new generation ...
(Date:6/2/2015)... TU-Automotive Detroit is the biggest dedicated B2B connected ... senior execs from GM, Chrysler, Mercedes, Ford, TomTom, Zipcar, ... status update on the automotive technology industry and a ... to secure one of the remaining passes. , Justin ... There are 70 sessions looking across the connected car ...
(Date:6/2/2015)... CRN International has been named a 2015 Company Partner ... Connecticut state program that takes active steps to train, coach ... companies. , Platform to Employment is being delivered by ... Labor. CRN, a 40-year-old radio marketing company near New Haven, ... for its “hard work and dedication.” , CRN recently took ...
Breaking Medicine News(10 mins):Health News:Acara Partners Expands Website and Digital Offerings 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2Health News:ANT Technology Incorporated in Second Generation WASP Bridge Products 2Health News:ANT Technology Incorporated in Second Generation WASP Bridge Products 3Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:CRN Named Company Partner of the Year by CT Employment Program 2
... Angeles Universities, VSP(R) Vision Care and Transitions Optical ... Their Eye Health, PINELLAS PARK, Fla., Nov. 7 ... Career College, Hacienda La,Puente Adult Education and VSP(R) Vision ... Hispanic community at the American Diabetes,Association,s Feria de Salud ...
... officials,traveling the state to gain insight and raise public ... to Bedford, Blair and Centre,counties today., The tour ... James is part of the Strategy for Agriculture and ... to address,food safety and defense from the farm to ...
... BioSpecifics,Technologies Corp. (OTC Bulletin Board: BSTC.OB), a ... that BioSpecifics, President, Tom Wegman, will present a,corporate ... Annual Healthcare,Conference on Wednesday, November 12, 2008, at ... New York, NY., A live webcast of ...
... Associates Also Names Kaiser Permanente "Highest in,Member Satisfaction" ... 7 Kaiser Permanente Colorado is the,top-ranked commercial ... according to a joint ranking by U.S. News ... Assurance (NCQA)., To view the Multimedia News ...
... October 31, 2008 -- Children under the age of three ... behavioral or developmental problems later compared to children who had ... at Columbia University Mailman School of Public Health and the ... children who were born into the New York State Medicaid ...
... by Charlie Rose at National Health Science Summit, ... the leader,in disease prevention, today announced Dr. Valentin ... its first-ever Global Prevention Prize.,The Prize was presented ... during the inaugural National Health Science Summit held ...
Cached Medicine News:Health News:Transitions Optical to Provide Free Vision Screenings at the American Diabetes Association's Feria de Salud por tu Familia(TM) 2Health News:Transitions Optical to Provide Free Vision Screenings at the American Diabetes Association's Feria de Salud por tu Familia(TM) 3Health News:Rendell Cabinet Secretaries Address Food Safety Concerns During Central PA Tour 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 3Health News:General anesthesia for hernia surgery in children and risk of later developmental problems 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
... practitioners consider the HOPE nebulizer the gold standard ... made to put everything together in one convenient ... is our #11320 Adult HOPE Kit which contains ... and pediatric aerosol mask all in one set ...
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
Medicine Products: